论文部分内容阅读
应用国产卡铂５００ｍｇ·ｄ－１连续３次疗法治疗既往化疗疗效不佳的晚期恶性肿瘤病人１２例，其中原发性肺癌６例和转移性肺癌３例，ＣＲ＋ＰＲ＋ＭＲ分别为４／６和２／３。食道癌２例，１例疗效达ＭＲ。血液和胃肠系统毒性反应发生率均比国内卡铂Ⅱ、Ⅲ期临床协作组资料高，１例病人死于尿毒症并发肺部感染。结果提示：该方案对晚期难治性非小细胞肺癌有一定的临床试用价值，但临床实施中必须注意防止其严重的肾功能损害。
Carboplatin 500mg·d-1 was used to treat 3 patients with advanced malignancy with poor efficacy in the past, including 6 primary lung cancers and 3 metastatic lung cancers. CR+PR+MR was 4/6 and 2/3 respectively. 3. Two cases of esophageal cancer, 1 case of efficacy of MR. The incidence of blood and gastrointestinal toxicity reactions was higher than that of domestic carboplatin II and III clinical collaboration groups. One patient died of uremia complicated with pulmonary infection. The results suggest that this protocol has a certain clinical trial value for advanced refractory non-small cell lung cancer, but the clinical implementation must pay attention to prevent its severe renal impairment.